U.S. Severe Oral Mucositis Market Analysis & Forecast: 2026-2033

U.S. Severe Oral Mucositis Market Size and Share Analysis - 2026 To 2033

The U.S. severe oral mucositis market size is estimated to total USD 138.3 Mn in 2026 and is projected to grow at a CAGR of 12.0% during the forecast period, reaching approximately USD 305.8 Mn by 2033. This is attributable to increasing incidence of cancer, rising adoption of chemotherapy and radiotherapy, and advancements in oral mucositis treatment options. In 2025, an estimated 2,041,910 new cancer cases and 618,120 cancer-related deaths are expected in the United States.

Key Takeaways from the U.S. Severe Oral Mucositis Market Report

• Palifermin is expected to account for the largest market revenue share of 31% in 2026 as it remains the only FDA-approved biologic specifically indicated for preventing severe oral mucositis in patients undergoing hematopoietic stem cell transplantation (HSCT).
• Radiotherapy segment is slated to lead the market with a share of 70% in 2026 due to rising prevalence of radiotherapy-induced severe oral mucositis, especially among head and neck cancer patients. For example, recent
• Hospital pharmacies segment is likely to hold 82% of the U.S. severe oral mucositis market share in 2026, as most severe oral mucositis therapies are administered within oncology centers and hospitals.

U.S. Severe Oral Mucositis Market Overview

The U.S. severe oral mucositis market is expected to register strong growth during the forecast period. This is primarily due to rising cancer burden, increasing adoption of chemotherapy and radiotherapy, and growing prevalence of treatment-induced severe oral mucositis. In addition, ongoing clinical research, introduction of novel therapies for oral mucositis management, and presence of leading pharmaceutical companies are also supporting market expansion across the United States.

Oral mucositis is an inflammatory condition of the oral mucosa that commonly develops as a side effect of cancer treatments such as chemotherapy and radiation therapy. The condition can significantly reduce nutritional intake by causing painful ulcers and difficulty eating or swallowing. In addition to affecting quality of life, oral mucositis increases the risk of infection because open sores in the mouth allow bacteria and other microorganisms to enter the body.

Growing incidence of cancer, especially oral cancers, is acting as a catalyst for the growth of severe oral mucositis market in the U.S. The . Radiotherapy is a standard treatment for many of these patients, particularly those with locally advanced disease, supporting a large population at risk for radiotherapy-induced oral mucositis. This, in turn, is expected to fuel demand for severe oral mucositis drugs in the country.

Increasing emphasis on supportive oncology care is also boosting U.S. severe oral mucositis market value. Oncology centers are increasingly prioritizing improvements in patients’ quality of life, reduction of treatment interruptions, and maintenance of nutritional status. Effective management of severe oral mucositis helps reduce hospitalizations, opioid use, infection risk, and treatment delays, thereby supporting broader adoption of approved therapies.

In addition, increasing investment in supportive oncology research is expected to create a conducive environment for the expansion of severe oral mucositis market across the U.S. during the forecast period. Manufacturers are investing in regenerative medicine, biologics, and mucosal protection technologies to address unmet clinical needs and expand treatment options for patients receiving intensive cancer therapies.

For example, the ongoing clinical trial of RRx-001 (EpicentRx) is evaluating its potential to reduce the severity and incidence of severe oral mucositis in patients undergoing chemoradiotherapy. Such developments are anticipated to provide a strong thrust to the growth of United States severe oral mucositis market in the coming years.

Segmental Insights 

To learn more about this report, Request Free Sample

Which Drug Type Dominates the U.S. Severe Oral Mucositis Market?

Palifermin Leads the Market with Nearly One-Third of Market Share

According to Coherent Market Insights’ latest U.S. severe oral mucositis market analysis, palifermin is set to dominate the market, accounting for a revenue share of 31% in 2026. This dominance is primarily attributed to its proven efficacy in reducing the incidence, severity, and duration of severe oral mucositis in patients undergoing high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT).

Palifermin is the only FDA-approved keratinocyte growth factor (KGF) specifically indicated to reduce the incidence and duration of severe oral mucositis in eligible HSCT patients. It continues to be the preferred pharmacological option in this setting due to its ability to stimulate the growth and repair of oral mucosal epithelial cells.

A 2022 meta-analysis of 10 randomized controlled trials showed that palifermin reduced the risk of severe oral mucositis by up to 30% in patients receiving treatment with chemotherapy and/or radiotherapy. The drug is expected to retain its leading position in the U.S. severe oral mucositis industry during the forecast period as it helps minimize treatment-related complications, improve patients' quality of life, and reduce the need for supportive interventions such as opioid analgesics and parenteral nutrition.

Which Cause Accounts for the Largest Share of the U.S. Severe Oral Mucositis Market?

Radiotherapy-Induced Oral Mucositis Dominates the U.S. Market 

To learn more about this report, Request Free Sample

Based on cause, radiotherapy segment is projected to lead the U.S. severe oral mucositis industry, accounting for a market share of around 70% in 2026. This is mostly due to high incidence of oral mucosal damage among patients receiving radiation therapy for head and neck cancers.

Radiotherapy directly exposes healthy oral tissues to ionizing radiation, which causes irritation, formation of ulcers, and pain, thereby requiring supportive treatment. The risk becomes greater still when radiation therapy is administered alongside chemotherapy.

Growing prevalence of head and neck cancers, increasing adoption of radiation-based treatment protocols, and improved cancer survival rates are expanding the number of patients at risk of severe oral mucositis. Head and neck cancers account for approximately 4% of all cancer diagnoses in the United States each year. As a result, demand for effective prevention and treatment strategies continues to rise, solidifying radiotherapy segment's leading position in the U.S. severe oral mucositis market.

U.S. Severe Oral Mucositis Market Growth Drivers

Rising Prevalence of Cancer

Increasing prevalence of cancer is providing a strong impetus for the growth of the U.S. severe oral mucositis market. There is a rise in cancer cases across the U.S. For example, according to the This growing cancer burden is expected to increase the adoption of chemotherapy, radiotherapy, and hematopoietic stem cell transplantation (HSCT), thereby fueling demand for severe oral mucositis drugs.

The increasing number of patients undergoing chemotherapy, radiotherapy, and hematopoietic stem cell transplantation (HSCT) is directly contributing to a higher incidence of severe oral mucositis. Head and neck cancer patients receiving radiotherapy remain among the highest-risk populations, creating strong demand for preventive and therapeutic interventions.

U.S. Severe Oral Mucositis Market Opportunities

Growing Use of Radiotherapy and Combination Cancer Therapies

Increasing adoption of advanced cancer treatment regimens is expected to create lucrative growth opportunities for the U.S. severe oral mucositis market during the forthcoming period. Modern oncology protocols increasingly combine chemotherapy, radiotherapy, immunotherapy, and targeted therapies to improve treatment outcomes. These modalities, however, have increased the risk of development of oral mucositis, and hence the need for preventive and management strategies.

For instance, severe oral mucositis develops in nearly all patients receiving radiotherapy for head and neck cancers, while approximately 20% to 80% of patients undergoing chemotherapy experience oral mucositis. Thus, rising use of radiotherapy, especially for head and neck cancers, and growing adoption of combination cancer therapies are set to fuel demand for severe oral mucositis therapeutics and supportive care products across the U.S.

U.S. Severe Oral Mucositis Market Trends

Development of Novel Therapies

The development of novel therapies for severe oral mucositis is emerging as a key market trend in the U.S. Pharmaceutical companies are advancing innovative biologics, targeted therapies, and late-stage pipeline candidates designed to prevent or reduce the severity of oral mucositis while offering improved safety and efficacy over conventional treatment options.

For instance, Monopar Therapeutics completed a pre-specified interim analysis of its Phase 2b/3 VOICE trial of Validive for preventing severe oral mucositis in patients undergoing chemoradiotherapy for oropharyngeal cancer in March 2023. Increasing investment in research and development, coupled with ongoing clinical advancements, is expected to expand treatment options and support growth of the U.S. severe oral mucositis market during the forecast period.

Current Events and Their Impact on the U.S. Severe Oral Mucositis Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Who are the Major Companies in the U.S. Severe Oral Mucositis Market?

Some of the major players in U.S. severe oral mucositis market are Innovation Pharmaceuticals Inc., Monopar Therapeutics Inc., Soligenix, Inc., Oragenics, Inc., Enzychem Lifesciences, Galera Therapeutics, Inc., Amgen, Inc., and Covis Pharma Group.

Key Strategies Adopted by Industry Players:

Top manufacturers of severe oral mucositis drugs across the U.S. are adopting various organic and inorganic strategies to boost their revenue as well as gain a competitive edge in the industry. These include new product launches and approvals, investments in R&D activities, partnerships, mergers, acquisitions, collaborations, and distribution agreements.

• In October 2024, Jaguar Health launched Gelclair, an FDA-cleared prescription oral mucositis treatment gel in the U.S. It is the company’s third commercialized prescription product.
• In February 2023, Galera Therapeutics announced that the FDA accepted its NDA for avasopasem for review and granted Priority Review for radiotherapy-induced severe oral mucositis.

Market Report Scope 

Analyst Opinion (Expert Opinion)

• Severe oral mucositis remains one of the most common side effects of cancer treatment. Studies show it occurs in almost all patients receiving radiotherapy for head and neck cancer and in 20%–80% of patients receiving chemotherapy, making supportive care an essential part of oncology treatment rather than an optional add-on.
• The U.S. severe oral mucositis market is to grow rapidly mostly due to rising cancer treatment volumes than by disease prevalence alone. As more patients receive intensive chemotherapy, radiotherapy, and stem cell transplants, the need for effective oral mucositis management continues to grow.
• Hospitals are placing greater emphasis on keeping patients on their planned cancer treatment schedule. Better management of severe oral mucositis helps reduce treatment interruptions, making supportive care products increasingly valuable in oncology practice.
• The future U.S. severe oral mucositis treatment market outlook will rely on treatment methods which will prevent the occurrence of mucositis rather than simply treating it. Treatments that decrease both the severity and the duration of oral mucositis should be more widely accepted.

Market Segmentation

• By Drug Type Insights ( Revenue, USD Mn, 2021 - 2033)
  • Palifermin
  • Amifostine
  • Chlorhexidine
  • Sucralfate
  • Late Phase (Avasopasem and Dusquetide)
• By Cause Insights ( Revenue, USD Mn, 2021 - 2033)
  • Chemotherapy
  • Radiotherapy
• By Grade Insights ( Revenue, USD Mn, 2021 - 2033)
  • Grade III
  • Grade IV
• By Distribution Channel Insights ( Revenue, USD Mn, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Sources

Primary Research Interviews

• Oncologists
• Radiation Oncologists
• Hematologists
• Oral Medicine Specialists
• Oncology Pharmacists
• Hospital Procurement Managers
• Clinical Researchers
• Academic Experts
• Key Opinion Leaders (KOLs)

Databases

• PubMed
• MEDLINE
• Embase
• ClinicalTrials.gov
• SEER (Surveillance, Epidemiology, and End Results Program)
• National Cancer Database (NCDB)
• FDA Drugs Database
• NIH RePORTER

Magazines

• Oncology Times
• Cancer Today
• Pharmacy Today
• Managed Healthcare Executive
• Drug Topics

Journals

• Supportive Care in Cancer
• Oral Oncology
• Journal of Clinical Oncology
• The Oncologist
• Cancer Medicine
• JAMA Oncology
• BMC Cancer
• International Journal of Radiation Oncology, Biology, Physics

Newspapers

• The New York Times
• The Wall Street Journal
• USA Today
• The Washington Post
• Financial Times

Associations

• American Society of Clinical Oncology (ASCO)
• Multinational Association of Supportive Care in Cancer (MASCC)
• Oncology Nursing Society (ONS)
• American Association for Cancer Research (AACR)
• American Cancer Society (ACS)
• National Comprehensive Cancer Network (NCCN)
• International Society of Oral Oncology (ISOO)

Public Domain Sources

• U.S. Food and Drug Administration (FDA)
• National Cancer Institute (NCI)
• National Institutes of Health (NIH)
• Centers for Disease Control and Prevention (CDC)
• World Health Organization (WHO)
• Agency for Healthcare Research and Quality (AHRQ)
• Centers for Medicare & Medicaid Services (CMS)
• U.S. Census Bureau

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for Last 10 Years